Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NANT Colorectal Cancer (CRC) Vaccine: A Phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects With Metastatic CRC Who Have Been Previously Treated With Standard-of-Care Therapy

Next Previous
Trial Profile

NANT Colorectal Cancer (CRC) Vaccine: A Phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects With Metastatic CRC Who Have Been Previously Treated With Standard-of-Care Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldoxorubicin (Primary) ; ALT 803 (Primary) ; Avelumab (Primary) ; Brachyury peptide vaccine (Primary) ; Capecitabine (Primary) ; CD16 and interleukin 2 expressing natural killer cells-NantKwest (Primary) ; Cetuximab (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; ETBX 021 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; GI 4000 (Primary) ; GI 6207 (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Regorafenib (Primary) ; Trastuzumab (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NantKwest

    • Most Recent Events

    • 15 May 2019 Status changed from recruiting to active, no longer recruiting.
    • 14 Jan 2019 According to a CytRx Corporation media release, aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the phase 1b portion of this phase 1b/2 trial.
    • 28 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top